Using methylation analyses in primary breast cancer specimens, Kagara and colleagues found that MSI-1 promotor methylation (which was inversely correlated with gene expression) was lowest in TNBC, similar to other stem cell markers, including CD44 and CD133 [62–64]. Here, CD44 is linked to breast cancer.